Cytosine-1-beta-D-arabinofuranoside en es it fr

Cytosine-1-beta-D-arabinofuranoside Brand names, Cytosine-1-beta-D-arabinofuranoside Analogs

Cytosine-1-beta-D-arabinofuranoside Brand Names Mixture

  • No information avaliable

Cytosine-1-beta-D-arabinofuranoside Chemical_Formula


Cytosine-1-beta-D-arabinofuranoside RX_link

Cytosine-1-beta-D-arabinofuranoside fda sheet

Cytosine-1-beta-D-arabinofuranoside msds (material safety sheet)

Cytosine-1-beta-D-arabinofuranoside MSDS

Cytosine-1-beta-D-arabinofuranoside Synthesis Reference

Krenitski, et al; Carbohydr.Res.; 97, 139-146(1981)

Cytosine-1-beta-D-arabinofuranoside Molecular Weight

243.217 g/mol

Cytosine-1-beta-D-arabinofuranoside Melting Point


Cytosine-1-beta-D-arabinofuranoside H2O Solubility

Freely soluble

Cytosine-1-beta-D-arabinofuranoside State


Cytosine-1-beta-D-arabinofuranoside LogP


Cytosine-1-beta-D-arabinofuranoside Dosage Forms

Injectable solution

Cytosine-1-beta-D-arabinofuranoside Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytosine-1-beta-D-arabinofuranoside Pharmacology

Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.

Cytosine-1-beta-D-arabinofuranoside Absorption

Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.

Cytosine-1-beta-D-arabinofuranoside side effects and Toxicity

Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.

Cytosine-1-beta-D-arabinofuranoside Patient Information

This medicine is a type of chemotherapy for treating cancers of the
blood and certain other cancers. This medicine interfers with the
way cancer cells grow, Take your doses on a regular scheduled time
and DO NOT take this medicine more often than directed by your health
care provider. Finish the full course prescribed by your health care
provider. DO NOT stop taking this medicine unless diredted to do so
by your health care provider. While taking this medicine, you make
get infection more easily. Call your doctor if you get a fever, chills,
or sore throat. Drink plenty of water with this medicine.

Cytosine-1-beta-D-arabinofuranoside Organisms Affected

Humans and other mammals